First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts
Emiliano Calvo(South Texas Accelerated Research Therapeutics), Patricia LoRusso(Yale Cancer Center), Mark J. Ratain(University of Chicago), Adam M. Petrich(AbbVie (United States)), Drew Rasco(Texas Oncology), Yu‐Wei Chang(National Defense Medical Center), Sudhir Penugonda(ClearMotion (United States)), Maja J.A. de Jonge(Erasmus MC Cancer Institute), Mona Motwani(UMass Memorial Health Care), Vicente Moreno, Manoj Chiney(AbbVie (United States))
Cited by 1
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799